Literature DB >> 35362829

Clinical predictors of survival for patients with atypical teratoid/rhabdoid tumors.

Vismaya S Bachu1, Pavan Shah2, Adrian E Jimenez2, Adham M Khalafallah2, Jignesh Tailor3,4, Debraj Mukherjee2, Alan R Cohen2.   

Abstract

PURPOSE: Atypical teratoid/rhabdoid tumors (AT/RTs) are malignant central nervous system (CNS) neoplasms of the young. Our study analyzed a large AT/RT cohort from the National Cancer Database (NCDB) to elucidate predictors of short-term mortality and overall survival (OS).
METHODS: Information was collected on patients with histologically confirmed AT/RT using the NCDB (2004-2016). Kaplan-Meier analysis indicated OS. Prognostic factors for 30-day mortality, 90-day mortality, and OS were determined via multivariate Cox proportional hazards (CPH) and logistic regression models.
RESULTS: Our cohort of 189 patients had a median age of 1 year (IQR [1, 4]) and tumor size of 4.7 ± 2.0 cm at diagnosis. Seventy-two percent were under 3 years old; 55.6% were male and 71.0% were Caucasian. Fifty (27.2%) patients received only surgery (S) (OS = 5.91 months), 51 (27.7%) received surgery and chemotherapy (S + CT) (OS = 11.2 months), and 9 (4.89%) received surgery and radiotherapy (S + RT) (OS = 10.3 months). Forty-five (24.5%) received S + CT + RT combination therapy (OS = 45.4 months), 13 (17.1%) received S + CT + BMT/SCT (bone marrow or stem cell transplant) (OS = 55.5 months), and 16 (8.70%) received S + CT + RT + BMT/SCT (OS = 68.4 months). Bivariate analysis of dichotomized age (HR = 0.550, 95% CI [0.357, 0.847], p = 0.0067) demonstrated significantly increased patient survival if diagnosed at or above 1 year old. On multivariate analysis, administration of S + CT + RT, S + CT + BMT/SCT, or S + CT + RT + BMT/SCT combination therapy predicted significantly (p < 0.05) increased OS compared to surgery alone.
CONCLUSION: AT/RTs are CNS tumors where those diagnosed under 1 year old have a significantly worse prognosis. Our study demonstrates that while traditional CT, RT, and BMT/SCT combination regimens prolong life, overall survival in this population is still low.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  National Cancer Database Study; Pediatric NCDB; Pediatric brain tumor; Pediatric tumor

Mesh:

Year:  2022        PMID: 35362829     DOI: 10.1007/s00381-022-05511-w

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.532


  19 in total

1.  Complications following pediatric cranioplasty after decompressive craniectomy: a multicenter retrospective study.

Authors:  Brandon G Rocque; Bonita S Agee; Eric M Thompson; Mark Piedra; Lissa C Baird; Nathan R Selden; Stephanie Greene; Christopher P Deibert; Todd C Hankinson; Sean M Lew; Bermans J Iskandar; Taryn M Bragg; David Frim; Gerald Grant; Nalin Gupta; Kurtis I Auguste; Dimitrios C Nikas; Michael Vassilyadi; Carrie R Muh; Nicholas M Wetjen; Sandi K Lam
Journal:  J Neurosurg Pediatr       Date:  2018-06-08       Impact factor: 2.375

2.  Trimodality therapy for atypical teratoid/rhabdoid tumor is associated with improved overall survival: A surveillance, epidemiology, and end results analysis.

Authors:  Thomas J Quinn; Muayad F Almahariq; Zaid A Siddiqui; Andrew B Thompson; Daniel A Hamstra; Peyman Kabolizadeh; Kate L Gowans; Peter Y Chen
Journal:  Pediatr Blood Cancer       Date:  2019-08-28       Impact factor: 3.167

3.  Patient-Level Factors Influencing Hospital Costs and Short-Term Patient-Reported Outcomes After Transsphenoidal Resection of Sellar Tumors.

Authors:  Jian Guan; Michael Karsy; Erica F Bisson; William T Couldwell
Journal:  Neurosurgery       Date:  2018-10-01       Impact factor: 4.654

4.  Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature.

Authors:  Mary Fossey; Haocheng Li; Samina Afzal; Anne-Sophie Carret; David D Eisenstat; Adam Fleming; Juliette Hukin; Cynthia Hawkins; Nada Jabado; Donna Johnston; Tania Brown; Valerie Larouche; Katrin Scheinemann; Douglas Strother; Beverly Wilson; Shayna Zelcer; Annie Huang; Eric Bouffet; Lucie Lafay-Cousin
Journal:  J Neurooncol       Date:  2017-01-19       Impact factor: 4.130

5.  Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the National Cancer Database.

Authors:  Benjamin W Fischer-Valuck; Ishita Chen; Amar J Srivastava; John M Floberg; Yuan James Rao; Allison A King; Eric T Shinohara; Stephanie M Perkins
Journal:  Cancer       Date:  2016-11-02       Impact factor: 6.860

6.  Risk factors for unplanned readmission within 30 days after pediatric neurosurgery: a nationwide analysis of 9799 procedures from the American College of Surgeons National Surgical Quality Improvement Program.

Authors:  Brandon A Sherrod; James M Johnston; Brandon G Rocque
Journal:  J Neurosurg Pediatr       Date:  2016-05-17       Impact factor: 2.375

7.  Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors.

Authors:  Iyad Sultan; Ibrahim Qaddoumi; Carlos Rodríguez-Galindo; Anwar Al Nassan; Khalil Ghandour; Maysa Al-Hussaini
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

8.  Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials.

Authors:  Santhosh A Upadhyaya; Giles W Robinson; Arzu Onar-Thomas; Brent A Orr; Pascal Johann; Gang Wu; Catherine A Billups; Ruth G Tatevossian; Sandeep Kumar Dhanda; Ashok Srinivasan; Alberto Broniscer; Ibrahim Qaddoumi; Anna Vinitsky; Gregory T Armstrong; Anne E Bendel; Tim Hassall; Sonia Partap; Paul G Fisher; John R Crawford; Murali Chintagumpala; Eric Bouffet; Sridharan Gururangan; Roya Mostafavi; Robert P Sanders; Paul Klimo; Zoltan Patay; Daniel J Indelicato; Kim E Nichols; Frederick A Boop; Thomas E Merchant; Marcel Kool; David W Ellison; Amar Gajjar
Journal:  Clin Cancer Res       Date:  2021-03-18       Impact factor: 12.531

9.  The Deyo-Charlson and Elixhauser-van Walraven Comorbidity Indices as predictors of mortality in critically ill patients.

Authors:  Karim S Ladha; Kevin Zhao; Sadeq A Quraishi; Tobias Kurth; Matthias Eikermann; Haytham M A Kaafarani; Eric N Klein; Raghu Seethala; Jarone Lee
Journal:  BMJ Open       Date:  2015-09-08       Impact factor: 2.692

10.  Atypical teratoid rhabdoid tumors: a population-based clinical outcomes study involving 174 patients from the Surveillance, Epidemiology, and End Results database (1973-2010).

Authors:  Christine Sm Lau; Krishnaraj Mahendraraj; Ronald S Chamberlain
Journal:  Cancer Manag Res       Date:  2015-09-18       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.